Braveheart Bio (NASDAQ:BRVE) Trading 5.9% Higher – Here’s Why

Braveheart Bio, Inc. (NASDAQ:BRVE) shares traded up 5.9% during trading on Wednesday . The company traded as high as $27.99 and last traded at $28.29. Approximately 42,524 shares changed hands during trading, a decline of 87% from the average daily volume of 339,641 shares. The stock had previously closed at $26.71.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. TD Cowen assumed coverage on Braveheart Bio in a research report on Monday, August 31st. They issued a “buy” rating for the company. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Braveheart Bio Stock Up 3.9%

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($2.26). On average, analysts expect that Braveheart Bio, Inc. will post -1.48 EPS for the current fiscal year.

Insider Activity

In related news, Director Orbimed Advisors Llc purchased 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the purchase, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This trade represents a 19.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Christopher Viehbacher purchased 83,333 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average price of $18.00 per share, for a total transaction of $1,499,994.00. Following the acquisition, the director owned 609,519 shares in the company, valued at $10,971,342. The trade was a 15.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 8,751,942 shares of company stock valued at $157,534,956 in the last ninety days.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.